KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Net Margin (2016 - 2025)

Historic Net Margin for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to 37.34%.

  • Vertex Pharmaceuticals' Net Margin rose 59900.0% to 37.34% in Q4 2025 from the same period last year, while for Dec 2025 it was 32.94%, marking a year-over-year increase of 378000.0%. This contributed to the annual value of 32.94% for FY2025, which is 378000.0% up from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Net Margin of 37.34% as of Q4 2025, which was up 59900.0% from 35.2% recorded in Q3 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Net Margin peaked at 42.94% during Q3 2021, and registered a low of 135.83% during Q2 2024.
  • For the 5-year period, Vertex Pharmaceuticals' Net Margin averaged around 26.08%, with its median value being 36.82% (2022).
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Net Margin tumbled by -1725600bps in 2024, and later surged by 1706700bps in 2025.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Net Margin stood at 37.16% in 2021, then fell by -4bps to 35.56% in 2022, then increased by 8bps to 38.48% in 2023, then dropped by -19bps to 31.35% in 2024, then rose by 19bps to 37.34% in 2025.
  • Its last three reported values are 37.34% in Q4 2025, 35.2% for Q3 2025, and 34.84% during Q2 2025.